ClinicalTrials.gg
Not yet recruitingNCT07945379CMV-TX-2025Updated Nov 18, 2026

Cytomegalovirus Infection After Transplantation: a Study of New Markers to Optimize the Selection of Antiviral Therapies and Reduce the Risk of Developing Direct and Indirect Infection-related Complications

An interventional study of CMV-RNAemia and CMV-DNAemia in Citomegalovirus Infection, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Not applicable, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Background and Rationale Cytomegalovirus (CMV) remains a major cause of morbidity and mortality in recipients of solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT). Current management relies on antiviral prophylaxis or pre-emptive therapy guided primarily by CMV-DNAemia monitoring. However, recently introduced antivirals such as letermovir and maribavir have changed the virological profile of CMV infection, highlighting limitations of DNAemia as a marker of active viral replication and increasing the need for improved resistance monitoring.

Preliminary studies suggest that CMV-RNAemia (UL21.5 mRNA) may be a more accurate marker of active viral replication and may detect viral clearance approximately 7-14 days earlier than CMV-DNAemia. In parallel, Next Generation Sequencing (NGS) may provide superior detection of antiviral resistance mutations, including low-frequency variants that cannot be identified by conventional Sanger sequencing.

Primary Objective To determine whether using CMV-RNAemia to guide discontinuation of antiviral therapy in transplant recipients can reduce treatment duration and drug-related toxicity without increasing the risk of CMV relapse, compared with the current standard based on CMV-DNAemia.

Secondary Objectives

Compare the diagnostic performance of NGS and Sanger sequencing in detecting CMV antiviral resistance mutations.

Estimate the incidence of resistant or refractory CMV infection (R/R-CMV) in transplant recipients.

Identify risk factors associated with the development of R/R-CMV according to transplant type.

Study Design This is a single-center, pragmatic, randomized controlled interventional study conducted at the IRCCS Azienda Ospedaliero-Universitaria di Bologna.

Adult transplant recipients (≥18 years) with CMV infection requiring antiviral therapy will be randomized (1:1) into two groups:

Experimental arm: antiviral therapy discontinued after two consecutive negative CMV-RNAemia results.

Control arm: antiviral therapy discontinued after two consecutive negative CMV-DNAemia results.

Patients will be followed from treatment initiation, with virological monitoring continuing during therapy and follow-up.

Population and Sample Size The study plans to enroll approximately 330 CMV infection episodes, including an estimated 10% drop-out rate, with 150 participants per study arm plus additional cases to compensate for losses.

Endpoints Primary endpoints include:

Time to treatment discontinuation. Time to viral clearance. Incidence and timing of clinically significant CMV relapse. Antiviral drug toxicity.

Secondary endpoints include:

Sensitivity, specificity, and predictive value of NGS versus Sanger sequencing. Incidence of resistant/refractory CMV infection. Identification of clinical and virological risk factors for resistance.

Resistance Analysis In suspected resistant or refractory CMV infections, residual biological samples will undergo NGS analysis targeting CMV genes involved in antiviral resistance (UL97, UL54, UL56, UL89, UL27, UL51). Results will be compared with standard Sanger sequencing to assess earlier detection of resistance mutations and minor viral variants.

Expected Impact The study aims to establish CMV-RNAemia as a clinically useful marker for earlier identification of viral clearance, enabling shorter antiviral treatment and reduced toxicity. It also seeks to validate NGS-based resistance testing as a more sensitive tool for detecting emerging CMV drug resistance, ultimately supporting a more personalized approach to CMV management in transplant recipients and potentially other immunocompromised populations.

Study Duration and Funding The study is expected to last 24 months (18 months recruitment, 4 months follow-up, 2 months analysis) and is funded by the Italian Ministry of Health (Ricerca Corrente 2026, project RC-2026-2802099).

02

Conditions studied

  • Citomegalovirus Infection

Keywords

  • CMV
  • Citomegalovirus
03

In context

Lead sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna is the lead sponsor of 517 studies on the registry; 292 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • CSE/SOT transplant patient;
  • Currently receiving antiviral medication;
  • Age ≥ 18 years
  • Signed form for participation and data processing

Exclusion criteria

Exclusion Criteria:

  • Localized CMV infection / organ disease.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
330 participants (estimated)

Study arms

  • Experimental
    Antiviral therapy will be discontinued after two consecutive negative results for CMV-RNAemia

    Other: CMV-RNAemia · Other: CMV-DNAemia

  • Active comparator
    Antiviral therapy will be discontinued after two consecutive negative results for CMV-DNAemia

    Other: CMV-DNAemia

Interventions

  • OtherCMV-RNAemia

    From enrollment (time 0, t0) until viral clearance is achieved (tn), all remaining biological material from blood samples analyzed for the monitoring/diagnosis of CMV infection will be collected and stored. Plasma samples will be analyzed for the presence of UL21.5 mRNA (CMV-RNAemia UL21.5) using the automated CMV-RNA ELITe MGB kit on an InGenius instrument (ELITech Group).

  • OtherCMV-DNAemia

    During the treatment period and the follow-up period, patients will be monitored in accordance with current clinical practice through serial virologic assessments (CMV-DNAemia) and the collection of relevant clinical data. Assessments will be conducted weekly during the first three months after transplantation, every 15 days from the fourth to the sixth month, and then monthly from the seventh to the twelfth month. For the purposes of evaluating the primary endpoint, the first four months of follow-up will be taken into account.

06

What researchers measure

Primary outcomes

  1. CMV-DNAemia VS CMV-DNAemia 1

    To determine whether the use of CMV-RNAemia to guide the discontinuation of antiviral therapy in transplant recipients (SOT and CSE) results in a reduction in the duration of treatment exposure compared to the standard strategy based on CMV-DNAemia, and a possible reduction in toxicity from anti-CMV drugs, without increasing the risk of recurrence of the infection. Measure: Time to discontinuation of therapy

    Time frame: Periprocedural

  2. CMV-DNAemia VS CMV-DNAemia 2

    To determine whether the use of CMV-RNAemia to guide the discontinuation of antiviral therapy in transplant recipients (SOT and CSE) results in a reduction in the duration of treatment exposure compared to the standard strategy based on CMV-DNAemia, and a possible reduction in toxicity from anti-CMV drugs, without increasing the risk of recurrence of the infection. Measure: Time to viral clearance

    Time frame: Periprocedural

  3. CMV-DNAemia VS CMV-DNAemia 3

    To determine whether the use of CMV-RNAemia to guide the discontinuation of antiviral therapy in transplant recipients (SOT and CSE) results in a reduction in the duration of treatment exposure compared to the standard strategy based on CMV-DNAemia, and a possible reduction in toxicity from anti-CMV drugs, without increasing the risk of recurrence of the infection. Measure: Incidence and time to recurrence of clinically significant CMV infection

    Time frame: Follow-up analysis (up to 4 months)

  4. CMV-DNAemia VS CMV-DNAemia 4

    To determine whether the use of CMV-RNAemia to guide the discontinuation of antiviral therapy in transplant recipients (SOT and CSE) results in a reduction in the duration of treatment exposure compared to the standard strategy based on CMV-DNAemia, and a possible reduction in toxicity from anti-CMV drugs, without increasing the risk of recurrence of the infection. Measure: Toxicity associated with anti-CMV drugs

    Time frame: Periprocedural

Secondary outcomes

  1. Sanger sequencing VS NGS sequencing 1

    Evaluate the diagnostic performance of NGS sequencing compared to the Sanger method in identifying CMV mutations associated with drug resistance, including minor variants. Measure: Sensitivity and specificity of NGS compared to Sanger

    Time frame: Follow up analysis (up to 1 year)

  2. Incidence of refractory CMV infection

    To estimate the incidence of resistant or refractory CMV infection (R/R CMV) in transplant recipients (SOT and CSE). Measure: Incidence of resistant or refractory CMV infection

    Time frame: Follow up analysis (up to 1 year)

  3. Risk factors for refractory CMV infection

    To compare the risk factors associated with the development of resistant or refractory CMV infection (R/R CMV) by type of transplant. Measure: Risk factors associated with resistant or refractory CMV infection

    Time frame: Follow up analysis (up to 1 year)

  4. Sanger sequencing VS NGS sequencing 2

    Evaluate the diagnostic performance of NGS sequencing compared to the Sanger method in identifying CMV mutations associated with drug resistance, including minor variants. Measure: Predictive value of NGS compared to Sanger

    Time frame: Follow up analysis (up to 1 year)

  5. Sanger sequencing VS NGS sequencing 3

    Evaluate the diagnostic performance of NGS sequencing compared to the Sanger method in identifying CMV mutations associated with drug resistance, including minor variants. Measure: Time required to identify mutations using NGS compared to Sanger

    Time frame: Follow up analysis (up to 1 year)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Jun 2028, 19 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2026
First posted
Nov 18, 2026
StartEst.
Nov 2026
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945379
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Tiziana Lazzarotto, MD
Contact
tiziana.lazzarotto@unibo.it
0512143360 ext. +39
Giulia Piccirilli, MD
Contact
giulia.piccirilli@aosp.bo.it

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion